Point mutants of FGFR2 bind and are inactivated by tyrosine kinase inhibitors

FGFR2 is inhibited by a range of in vitro tyrosine kinase inhibitors, including PD170734 and SU5402 (reviewed in Greulich and Pollock, 2010; Wesche, 2011). In addition, there are a number of FGFR2 inhibitors currently in clinical trials that for treatment of solid malignancies (http://ClinicalTrials.gov).

FGFR2受多种体外酪氨酸激酶抑制剂所抑制，其中包括PD170734和SU5402（详见Greulich和Pollock，2010；Wesche，2011之综述）。此外，目前尚有多种FGFR2抑制剂处于临床试验阶段，旨在治疗实体恶性肿瘤（参见http://ClinicalTrials.gov）。